The position of strontium ranelate in today’s management of osteoporosis

[1]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[2]  J. Reginster.  Cardiac concerns associated with strontium ranelate , 2014, Expert opinion on drug safety.

[3]  J. Compston.  Strontium ranelate lives to fight another day. , 2014, Maturitas.

[4]  Emanuela Falaschetti,et al.  Hypertension management in England: a serial cross-sectional study from 1994 to 2011 , 2014, The Lancet.

[5]  H. Svanström,et al.  Use of strontium ranelate and risk of acute coronary syndrome: cohort study , 2014, Annals of the rheumatic diseases.

[6]  C. Cooper,et al.  A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis: the impact of severe osteoporosis and contraindications , 2014 .

[7]  M. Hiligsmann,et al.  A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis , 2014, PharmacoEconomics.

[8]  D. Juurlink,et al.  Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis , 2014, Osteoporosis International.

[9]  E. Grove,et al.  Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate , 2014, Osteoporosis International.

[10]  J. Borer,et al.  Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case–control study in the CPRD , 2013, Osteoporosis International.

[11]  R. Rizzoli,et al.  SCOPE: a scorecard for osteoporosis in Europe , 2013, Archives of Osteoporosis.

[12]  E. McCloskey,et al.  A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years , 2013, Rheumatology International.

[13]  R. Francis,et al.  Treatment of osteoporosis in women intolerant of oral bisphosphonates. , 2012, Maturitas.

[14]  C. Cooper,et al.  Partial adherence: a new perspective on health economic assessment in osteoporosis , 2011, Osteoporosis International.

[15]  M. Hiligsmann,et al.  Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. , 2010, Bone.

[16]  M. Hiligsmann,et al.  Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women , 2009, Osteoporosis International.

[17]  J. Reginster,et al.  Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women , 2008, Osteoporosis International.

[18]  J. Cramer,et al.  Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. , 2006, The American journal of medicine.

[19]  J. Reginster,et al.  Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. , 2005, The Journal of clinical endocrinology and metabolism.

[20]  T. Spector,et al.  Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.